Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
228
datasets available to search
ShareScore release 0.9.0
Dataset results
228 results for “Valsartan”
Diva - The Effects Of 12 Weeks Of Treatment With High Dose Valsartan (320 Mg) To Amlodipine On Endothelial Function In Hypertensive Subjects With The Metabolic Syndrome
ClinicalTrials.gov study NCT00241150. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Study to Evaluate Efficacy of Micardis® (Telmisartan) and Valsartan in Patients With Mild-to-moderate Hypertension After Missing One Dose Using Ambulatory Blood Pressure Monitoring
ClinicalTrials.gov study NCT02242318. IPD Sharing: Not stated. Countries: 0. Publications: 0.
A Year Long Study to Evaluate the Safety of the Combination of Valsartan (320 mg) and Amlodipine (5 mg) in Patients With Hypertension
ClinicalTrials.gov study NCT00170976. IPD Sharing: Not stated. Countries: 2. Publications: 0.
Pharmacokinetic Interactions of Valsartan and Hydrochlorothiazide (Double Doses)
ClinicalTrials.gov study NCT01767298. IPD Sharing: Not stated. Countries: 0. Publications: 0.
The VALIDATE Study of Valsartan for Patients With Early Stage Heart Failure
ClinicalTrials.gov study NCT00241098. IPD Sharing: Not stated. Countries: 0. Publications: 0.
MICARDIS® and Valsartan in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring
ClinicalTrials.gov study NCT02177396. IPD Sharing: Not stated. Countries: 0. Publications: 0.
RAW DATA of the paper IMPROVEMENT OF FUNCTIONAL CAPACITY IN SACUBITRIL-VALSARTAN TREATED PATIENTS ASSESSED BY CARDIOPULMONARY EXERCISE TEST
<p>Neprilisin and angiotensin receptor inhibition (Sacubitril/Valsartan, i.e. ARNI) is recommended in heart failure guidelines for patients in NYHA class II-III with reduced left ventricular ejection fraction (LVEF). ARNI increase survival and quality of life; due to their hemodynamic effects, ARNI could also affect exercise tolerance. We studied the effects of ARNI on cardiopulmonary test (CPET) after six months of treatment in 35 patients [67±11 years; LVEF 31±6%; NT-proBNP 1822±1651 pg/ml; ICD/CRT since at least 6 months in 26/35], treated with increasing doses of Sacubitril/Valsartan up to 318±36 mg/die. In addition, levels of NT-proBNP, renal function, electrolytes, and echocardiocolorDoppler were assessed in the same time periods. No variations of renal function and/or potassium levels were observed; NT-proBNP decreased. Most CPET variables were improved by ARNI (p<0.05): peak VO<sub>2</sub> and O<sub>2</sub> pulse increased (from 15.8±3.4 to 17.0±4.0 ml/Kg/min and from 11.5±2.5 to 12.6±2.4 ml/beat, respectively), while VEVCO<sub>2</sub> slope decreased from 35.2±11.2 to 33.1±12.3. A significant relationship (p<0.05) was observed between the amount of increase in LVEF and that of O<sub>2</sub> pulse in all patients, and between the amount of decrease in PAPs and that of VEVCO<sub>2</sub> slope in patients showing pulmonary hypertension in baseline. In a subgroup of 22 patients who already completed A 1 year follow-up, overall CPET improvement was maintained. In conclusion, already in the short term ARNI favorably affect cardiopulmonary response to exercise in heart failure patients; such a change seems to be preserved on a longer period.</p>
Green first-order derivative synchronous spectrofluorometric analysis of valsartan and metolazone in pharmaceutical and biological matrices
<p class="RSCB01COMAbstract"><span><span>In this work, a green facile, sensitive, and rapid spectrofluorometric method was developed to assay two antihypertensive drugs, namely, valsartan (VST) and metolazone (MTZ), in pharmaceutical and biological matrices. Both drugs exhibited intrinsic fluorescence which was significantly influenced by environmental factors such as solvent system and pH. However, simultaneous analysis of VST and MTZ by conventional spectrofluorimetry cannot be performed easily due to the severe overlap of their fluorescence spectra. Therefore, combination of synchronous and derivative spectrofluorimetry was investigated to solve such dilemma. The developed method relied on measuring the first-order derivative of synchronous flourescence intensity of the studied analytes in 0.1M acetic acid at </span>Δ<span>λ=160nm. The peak amplitudes of the recorded first-order derivative synchronous flourescence spectra of VST and MTZ were measured at 262.8nm (zero-crossing point of MTZ) and 236.0nm (zero-crossing point of VST) to simultaneously assay VST and MTZ, respectively. The method was optimised carefully to obtain maximum sensitivity and selectivity by investigation of different solvent systems, different pH, and different micelles. The optimum selectivity and sensitivity were obtained, using 0.1M acetic acid as a solvent. The proposed method had a linear concentration range (10.0–100.0 ngmL</span>⁻<sup><span>1</span></sup><span>) and a detection limit (<2.0 ng mL</span>⁻<sup><span>1</span></sup><span>) for each drug. Statistical analysis of the data manifested no significant differences between the developed spectrofluorimetric method and the comparison methods. The method validity ensures its appropriateness for quality control work. The developed spectrofluorimetric method was applied to assess the studied analytes in pharmaceutical preparations and biological fluids with high %recovery and low RSD values.</span> <span>The greenness of the method was implemented by three approaches involving the recently developed metric (AGREE) which ensured the eco-freindship and safety of the method.</span></span></p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.